Volume | 232,495 |
|
|||||
News | - | ||||||
Day High | 212.77 | Low High |
|||||
Day Low | 207.04 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Penumbra Inc | PEN | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
209.29 | 207.04 | 212.77 | 210.05 | 210.19 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
7,244 | 232,495 | $ 210.69 | $ 48,984,651 | - | 180.93 - 348.67 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:00:00 | 34,179 | $ 210.05 | USD |
Penumbra (PEN) Options Flow Summary
Penumbra Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
8.13B | 38.70M | - | 1.06B | 90.95M | 2.35 | 89.37 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Penumbra News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PEN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 221.99 | 224.30 | 208.10 | 218.93 | 202,278 | -11.94 | -5.38% |
1 Month | 234.92 | 240.40 | 208.10 | 222.48 | 349,985 | -24.87 | -10.59% |
3 Months | 254.95 | 277.34 | 208.10 | 238.54 | 340,732 | -44.90 | -17.61% |
6 Months | 198.42 | 277.34 | 180.93 | 229.21 | 368,359 | 11.63 | 5.86% |
1 Year | 278.06 | 348.67 | 180.93 | 257.57 | 377,227 | -68.01 | -24.46% |
3 Years | 285.64 | 348.67 | 114.865 | 231.06 | 308,336 | -75.59 | -26.46% |
5 Years | 139.21 | 348.67 | 107.50 | 209.68 | 361,826 | 70.84 | 50.89% |
Penumbra Description
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are primarily sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for the neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States. |